Surrozen (SRZN) vs X4 Pharmaceuticals (XFOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Surrozen (SRZN) has outperformed X4 Pharmaceuticals (XFOR) over the past year, gaining 82.9% versus a loss of 18.3%. Over five years, SRZN leads with a -73.5% price change compared with -98.2% for XFOR. Surrozen is the larger company by market cap ($328.7 million vs $276.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SRZN | XFOR |
|---|---|---|
| Share price | $27.97 | $2.79 |
| Market cap | $328.75M | $276.62M |
| 1-day change | +11.23% | -0.71% |
| YTD return | +11.26% | -29.75% |
| 1-year return | +82.87% | -18.31% |
| 5-year return | -73.48% | -98.21% |
| P/E ratio (TTM) | — | 139.50 |
| EPS (TTM) | $-39.08 | $0.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $37.83 | $4.83 |
| 52-week low | $11.39 | $2.70 |
| Distance from 52-week high | -26.06% | -42.24% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +73.04% | +315.77% |
| Average volume | 475.02K | 843.50K |
| Shares outstanding | 11.75M | 99.15M |
| Employees | 44 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SRZN has outperformed XFOR by 101.2 percentage points over the past year.
About Surrozen
SRZN stock →Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees
About X4 Pharmaceuticals
XFOR stock →X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees
SRZN vs XFOR FAQ
Which is bigger, Surrozen or X4 Pharmaceuticals?
Surrozen (SRZN) is larger, with a market capitalization of $328.75M compared with $276.62M for X4 Pharmaceuticals (XFOR).
Which stock has performed better over the past year, SRZN or XFOR?
SRZN returned +82.87% over the past 12 months, compared with -18.31% for XFOR (price return, excluding dividends). Past performance does not predict future results.
Are Surrozen and X4 Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.